Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating reaffirmed by research analysts at Cowen and Company in a report issued on Tuesday, August 29th. They presently have a $400.00 price target on the stock. Cowen and Company’s target price would indicate a potential upside of 81.58% from the stock’s current price.
Several other analysts also recently issued reports on the company. BidaskClub downgraded Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday, August 25th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a research report on Tuesday, August 22nd. Argus reissued a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a research report on Monday, August 14th. UBS AG reissued an “outperform” rating and set a $275.00 target price on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have assigned a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and a consensus target price of $274.69.
Allergan PLC. (NYSE AGN) traded down 1.52% on Tuesday, hitting $220.29. 3,347,884 shares of the stock traded hands. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market cap of $73.64 billion, a price-to-earnings ratio of 6.71 and a beta of 1.18. The stock has a 50-day moving average price of $231.75 and a 200 day moving average price of $236.59.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $3.35 EPS. On average, analysts anticipate that Allergan PLC. will post $16.25 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Intl Fcstone Inc. purchased a new stake in shares of Allergan PLC. in the second quarter worth about $1,626,000. Phocas Financial Corp. purchased a new stake in shares of Allergan PLC. in the second quarter worth about $150,000. Sentry Investment Management LLC boosted its position in Allergan PLC. by 1.0% during the second quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock worth $6,536,000 after purchasing an additional 265 shares in the last quarter. WFG Advisors LP boosted its position in Allergan PLC. by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in Allergan PLC. by 25.2% during the second quarter. Toronto Dominion Bank now owns 113,770 shares of the company’s stock worth $27,651,000 after purchasing an additional 22,873 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with our FREE daily email newsletter.